# Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects

> **NCT00413608** · PHASE1 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 140 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT00413608
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2011-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00413608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00413608, "Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00413608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*